Natera Inc NTRA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Stanley Druckenmiller says he's shorting U.S. bonds and staying out of China
-
Court Orders Permanent Injunction Against NeoGenomics' Accused RaDaR Assay, as Case Enters New Phase
-
Natera Announces Three New Signatera Publications; Includes Groundbreaking Overall Survival Data Published in Nature Medicine and also Released at ESMO
-
First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall Survival
-
Natera to Present New Signatera™ Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall Survival
-
Natera to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
-
Natera Reports Second Quarter 2024 Financial Results
-
Natera to Participate in the Canaccord Genuity 44th Annual Growth Conference
Trading Information
- Previous Close Price
- $126.30
- Day Range
- $127.58–130.85
- 52-Week Range
- $36.90–132.01
- Bid/Ask
- $128.98 / $130.09
- Market Cap
- $16.06 Bil
- Volume/Avg
- 1.1 Mil / 1.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 11.10
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier’s children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 3,018
- Website
- https://www.natera.com
Comparables
Valuation
|
Metric
|
NTRA
|
EXAS
|
TIHE
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 702.77 | — |
Price/Book Value | 18.63 | 3.84 | — |
Price/Sales | 11.10 | 4.63 | — |
Price/Cash Flow | — | 61.85 | — |
Price/Earnings
NTRA
EXAS
TIHE
Financial Strength
|
Metric
|
NTRA
|
EXAS
|
TIHE
|
|---|---|---|---|
Quick Ratio | 3.89 | 1.81 | 0.00 |
Current Ratio | 4.14 | 2.17 | 0.00 |
Interest Coverage | −24.80 | −7.23 | — |
Quick Ratio
NTRA
EXAS
TIHE
Profitability
|
Metric
|
NTRA
|
EXAS
|
TIHE
|
|---|---|---|---|
Return on Assets (Normalized) | −7.24% | 0.13% | — |
Return on Equity (Normalized) | −13.65% | 0.26% | — |
Return on Invested Capital (Normalized) | −10.16% | 0.43% | — |
Return on Assets
NTRA
EXAS
TIHE
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| Chmnnygjy | Lypy | $229.5 Bil | |||
| Danaher Corp
DHR
| Fgpwnxkp | Lyggdw | $195.4 Bil | |||
| Agilent Technologies Inc
A
| Vxbjgqcpx | Jglk | $41.5 Bil | |||
| IQVIA Holdings Inc
IQV
| Plcxhhp | Kccjnns | $41.5 Bil | |||
| IDEXX Laboratories Inc
IDXX
| Sqffyzwjj | Wcck | $39.8 Bil | |||
| Mettler-Toledo International Inc
MTD
| Vzxgfcjjj | Bjwwnm | $31.1 Bil | |||
| Icon PLC
ICLR
| Zctjfmrlt | Lklcv | $24.3 Bil | |||
| Illumina Inc
ILMN
| Wglfjghjj | Rtqshv | $21.7 Bil | |||
| Waters Corp
WAT
| Jghfwtqxlr | Sfm | $21.0 Bil | |||
| Labcorp Holdings Inc
LH
| Sjlyhndlm | Zvmsdz | $18.1 Bil |
United States